Yamanouchi Pharmaceutical Company Ltd.

Ferring B.v.

Feering B.v.

Ferring-research Limited

Michael Szelke

Mitsuaki Ohta

Keiji Miyata

Masato Satoh

Graeme Semple

Akito Nishida

Hamish Ryder

Paul D Jenkins

D Michael Jones

David Alan Kendrick

David Michael Evans

David Michael Jones

Masato Ishii

Compounds selected from those of general formula

Inhibitors of DP-mediated processes, compositions, and therapeutic methods thereof

Kininogenase inhibiting peptides or peptide analogues with C-terminal related to agmatine or noragmatine.

Kininogen inhibitors

A benzodiazepine derivative of formula (I), or a pharmaceutically acceptable salt thereof, wherein (a) R.sup.1 is --CH.sub.2 CHOH(CH.sub.2).sub.a R.sup.4 or a ketone group --CH.sub.2 CO(CH.sub.2).sub.a R.sup.5 in which a is 0 or 1 and R.sup.4 and R.sup.5 are selected from alkyl and cycloalkyl groups and saturated heterocyclic groups optionally substituted at a hetero-atom; (b) R.sup.2 and R.sup.3 are independently selected from aromatic carbocyclic and heterocylic residues; and (c) W and X are selected independently from halogen and hydrogen atoms and alkyl and alkoxy groups. These compounds are gastrin and/or CCK-B receptor antagonists. ##STR1##

Benzodiazepin derivatives useful as CCK-receptor antagonists

Inhibitors of DP-mediated processes, compositions and therapeutic

Process of preparing benzodiazepine compounds useful as antagonists of

Benzodiazepine derivatives useful as CCK-receptor antagonists

Growing community of inventors

Romsey, United Kingdom

Michael Szelke